OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

In December 2014, Pfizer and OPKO began an agreement to develop hGH-CTP for growth hormone deficiency in adults and children, and for children who are small for gestational age and fail to show ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Despite normal hormone levels in her blood tests ... 4 No formal studies have established a link between breast parenchymal growth and the Pfizer COVID-19 vaccine. Although these social media ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Healthcare giant Pfizer’s IBRANCE (palbociclib ... of overall survival is not yet mature. Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Additionally, Pfizer’s strategic focus on obesity treatments, despite cautious expectations for danuglipron, remains a significant growth area. The company’s robust acquisitions strategy ...